Effects of lowering LDL cholesterol on progression of kidney disease

Richard Haynes, David Lewis, Jonathan Emberson, Christina Reith, Lawrence Agodoa, Alan Cass, Jonathan Craig, Dick de Zeeuw, Bo Feldt-Rasmussen, Bengt Fellstrom, Adeera Levin, David Wheeler, Robert Walker, William Herrington, Colin Baigent, Martin Landray

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo. The main prespecified renal outcome was ESRD (defined as the initiation of maintenance dialysis or kidney transplantation). During 4.8 years of follow-up, allocation to simvastatin plus ezetimibe resulted in an average LDL cholesterol difference (SEM) of 0.96 (0.02) mmol/L compared with placebo. There was a nonsignificant 3% reduction in the incidence of ESRD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases with placebo; rate ratio, 0.97; 95% confidence interval [95% CI], 0.89 to 1.05; P=0.41). Similarly, allocation to simvastatin plus ezetimibe had no significant effect on the prespecified tertiary outcomes of ESRD or death (1477 [47.4%] events with treatment versus 1513 [48.3%] events with placebo; rate ratio, 0.97; 95%CI, 0.90 to 1.04; P=0.34) or ESRD or doubling of baseline creatinine (1189 [38.2%] events with treatment versus 1257 [40.2%] events with placebo; rate ratio, 0.93; 95% CI, 0.86 to 1.01; P=0.09). Exploratory analyses also showed no significant effect on the rate of change in eGFR. Lowering LDL cholesterol by 1mmol/L did not slowkidney disease progressionwithin 5 years in awide range of patients withCKD.

Original languageEnglish
Pages (from-to)1825-1833
Number of pages9
JournalJournal of The American Society of Nephrology
Volume25
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint Dive into the research topics of 'Effects of lowering LDL cholesterol on progression of kidney disease'. Together they form a unique fingerprint.

  • Cite this

    Haynes, R., Lewis, D., Emberson, J., Reith, C., Agodoa, L., Cass, A., Craig, J., de Zeeuw, D., Feldt-Rasmussen, B., Fellstrom, B., Levin, A., Wheeler, D., Walker, R., Herrington, W., Baigent, C., & Landray, M. (2014). Effects of lowering LDL cholesterol on progression of kidney disease. Journal of The American Society of Nephrology, 25(8), 1825-1833. https://doi.org/10.1681/ASN.2013090965